6,375 Shares in iShares Biotechnology ETF (NASDAQ:IBB) Purchased by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI bought a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 6,375 shares of the financial services provider’s stock, valued at approximately $843,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IBB. Darwin Wealth Management LLC purchased a new stake in iShares Biotechnology ETF during the 3rd quarter worth about $29,000. Highline Wealth Partners LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter worth about $30,000. Ashton Thomas Securities LLC purchased a new stake in shares of iShares Biotechnology ETF during the third quarter worth about $36,000. Modus Advisors LLC acquired a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at approximately $41,000. Finally, Voisard Asset Management Group Inc. purchased a new position in shares of iShares Biotechnology ETF during the third quarter valued at approximately $59,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.8 %

IBB stock opened at $138.37 on Tuesday. The company has a 50 day moving average price of $136.15 and a two-hundred day moving average price of $141.77. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were given a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.